Hepatitis C, Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial

Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial

table 1. Demographic Characteristics of the Patients

		Total	Sclerotherapy	TIPS

Patients	N°	81	43	38
Sex	M/F	58/23	31/12	27/11
Age (years)	Mean ± SD	59.2 ± 9.7	58.2 ± 10.7	60.5 ± 8.5
Stratum
I (1-7 days)	N° (%)	36 (44.5)	18 (41.9)	18 (47.4)
II (8 days-6 weeks)	N° (%)	33 (40.7)	18 (41.9)	15 (39.5)
III (7 weeks-6 months)	N° (%)	12 (14.8)	7 (16.2)	5 (13.1)
Etiology
Alcohol	N° (%)	21 (25.9)	15 (34.9)	6 (15.8)
Alcohol + HCV	N° (%)	4 (5.0)	2 (4.6)	2 (5.3)
Alcohol + HBV	N° (%)	1 (1.2)	0	1 (2.6)
Viral	N° (%)	46 (56.8)	19 (44.2)	27 (71.0)
HBV		7	4	3
HCV		33	11	22
HBV-HCV		6	4	2
Other	N° (%)	9 (11.1)	7 (16.3)	2 (5.3)
Lab tests
Albumin (g/dL)	mean ± SD	3.2 ± 0.5	3.3 ± 0.6	3.2 ± 0.4
PT (%)	mean ± SD	66 ± 16	66 ± 18	66 ± 14
Bilirubin (mg/dL)	mean ± SD	1.7 ± 1.3	1.8 ± 1.5	1.5 ± 1.0
Ascites
None	N° (%)	27 (33.3)	16 (37.2)	11 (28.9)
Slight	N° (%)	49 (60.5)	25 (58.1)	24 (63.2)
Refractory	N° (%)	5 (6.2)	2 (4.7)	3 (7.9)
Child’s class
A	N° (%)	26 (32.1)	13 (30.2)	13 (34.2)
B	N° (%)	45 (55.5)	25 (58.2)	20 (52.6)
C	N° (%)	10 (12.3)	5 (11.6)	5 (13.2)
Previous bleeds	N° (%)	31 (38.3)	16 (37.2)	15 (39.5)
Follow-up (weeks)	mean ± SD	76 ± 46	78 ± 47	74 ± 45

Return To Article

Table Of Contents

Share

Follow Us

Download Our Free Reports

Inside You'll Discover:

Thank You!